Multi-omic profiling of human and mouse dorsal root ganglia enables targeted gene delivery to nociceptors
简介:
- 作者: Lily S. He, Parth Bhatia, Shamsuddin A. Bhuiyan, Evangelia Semizoglou, Jiaxiang Wang, Jia Li, Joohyun Nam, Jay X. J. Luo, Chayse Arnhold, Difei Zhu, Mengyi Xu, Dustin Griesemer, Hyo Jeong Yong, Lorna Jayne, Evangeline Gilmer, Qiyi Li, Katerina Pantaleo, Lite Yang, Erika K. Williams, Selwyn Jayakar, Brian J. Wainger, Sinisa Hrvatin, View ORCID ProfileWilliam Renthal, NIH PRECISION Human Pain Network
- 杂志: BioRxiv
- Doi: https://www.doi.org/10.64898/2026.03.05.709931
- 出版日期: 2026/3/12
摘要
Chronic pain conditions are often driven by hyperexcitability of nociceptors, the peripheral sensory neurons that detect noxious stimuli. Recent single-cell transcriptomic studies have begun to clarify the molecular identity of distinct peripheral sensory neuron subtypes, but tools that restrict transgene expression to nociceptors while sparing other dorsal root ganglion (DRG) subtypes remain limited. Here, we combined single-nucleus multi-omic profiling of human and mouse DRG with in vivo AAV enhancer screening to identify cis-regulatory elements that drive biased AAV expression in mouse DRG nociceptors and human iPSC-derived nociceptors. We then validated that an enhancer AAV designed to express Kir2.1 preferentially in nociceptors reduces DRG neuronal excitability. Leveraging these multi-omic datasets, we trained a sequence-based model to decode the cis-regulatory logic of nociceptors, enabling both the prioritization of native candidate elements and the design of synthetic enhancers with a range of nociceptor targeting properties. Together, these cross-species multi-omic resources define conserved DRG regulatory programs and provide a viral toolkit for pain research with potential translational applications for patients with refractory pain.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。